Peter M. Ferguson

The University of Sydney

Papers

2

Total Citations

8

H-Index

2

About

Peter M. Ferguson is a urologic oncologist whose research centers on refining surgical approaches for genitourinary cancers, particularly testicular and prostate malignancies. His major contributions include advancing robotic-assisted retroperitoneal lymph node dissection (RPLND) for stage II testicular cancer, demonstrating its feasibility and safety through a prospective case series. This work, his most cited (6 citations), provides early evidence that robotic techniques can reduce morbidity while maintaining oncologic efficacy in this challenging patient population. Ferguson also leads the pilot phase of the NODE trial, a prospective multicenter randomized study investigating the role of extended pelvic lymph node dissection in high-risk prostate cancer. This protocol paper (2 citations) lays critical groundwork for determining whether more extensive nodal dissection improves outcomes, addressing a longstanding debate in urologic oncology. His research bridges the gap between surgical innovation and evidence-based practice, focusing on optimizing perioperative outcomes and oncologic control. By systematically evaluating these minimally invasive approaches, Ferguson is helping to define new standards for surgical management in testicular and prostate cancer, with implications for reducing treatment-related complications and improving patient recovery.

Research Focus

Key Achievements

2
H-Index
2
Papers
8
Total Citations
4
Avg Citations/Paper
🏆 Most Cited Paper
Robotic-assisted retroperitoneal lymph node dissection for stage II testicular cancer
6 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: The University of Sydney

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago